About QHP Capital
QHP Capital is a venture capital firm founded in 2022. It is primarily based out of United States. As of Jan 2023, QHP Capital has invested in 7 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to HealthTech and Life Sciences. Most recently it participated in the $***** Seed round of CoPilot Overall, QHP Capital portfolio has seen 3 acquisitions, namely Clinical Ink, Catalyst Clinical Research and CoreRx. QHP Capital has team of 15 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed
Portfolio Acquisitions
QHP Capital's List of Top Investments
QHP Capital has a portfolio of 7 companies. Their most notable investmentis in CoPilotTheir portfolio spans across and United States. They have invested in Enterprise Applications, HealthTech, Life Sciences and 2 other sectors, across stages such as Seed stage. Here is the list of top investments by QHP Capital:1. Clinical Ink
Clinical trial solutions provider specializing in eSource technology and patient-centric research. They offer a comprehensive suite of software and services designed to streamline clinical trials, improve data quality, and enhance patient engagement. Their eSource platform integrates direct data capture, electronic clinical outcome assessments, electronic consent, telehealth capabilities, sensors, wearables, and digital biomarkers. These solutions support decentralized clinical trials across various therapeutic areas, including diabetes, immunology, neurology, and oncology. The company focuses on providing innovative technology to improve the efficiency and accuracy of clinical research, ultimately driving better patient outcomes. Their offerings include cloud-based platforms, mobile device support, and data analytics capabilities. They aim to empower sponsors, CROs, and researchers with tools to recenter trials around the patient, facilitating faster and more reliable clinical development. They provide login access, support, and resources like white papers and webinars.
Key facts about Clinical Ink
- Founded Year: 2006
- Location: Winston-salem (United States)
- Stage: Acquired
- Total Funding till date: $14.8M
- Employee Count: 346 as on Aug 31, 2026
- Investors: SVB, QHP Capital and 5 Others
- Latest Funding Round: Venture Debt, May 14, 2018, $*****
- Highlight: Acquired
Key facts about Azurity Pharmaceuticals
- Founded Year: 1999
- Location: Woburn (United States)
- Annual Revenue: £0 - £1M as on Jul 26, 2023
- Stage: Early Stage
- Total Funding till date: $20M
- Employee Count: 1,062 as on Aug 31, 2026
- Investors: Athyrium Capital Management, QHP Capital and 2 Others
- Latest Funding Round: Unattributed, Dec 30, 2014, $*****
Catalyst Clinical Research is a full-service clinical research organization. They conduct clinical trials from phase I to 1V. Their services include clinical trial operation management, clinical data management, biostatistics, medical writing, pharmacovigilance, remote data review, and others.
Key facts about Catalyst Clinical Research
- Founded Year: 2013
- Location: Durham (United States)
- Stage: Acquired
- Employee Count: 250 as on Aug 31, 2026
- Investors: QHP Capital
- Highlight: Acquired
4. CoreRx
CoreRx is a contract pharmaceutical development organization that helps clients get into the clinic faster, providing a complete spectrum of cGMP solutions for pharmaceutical dosage form development. Their service offerings span the following: Pre-formulation, Analytical Development, Product Formulation, Clinical Manufacturing, Certified Clinical Facilities, Core Technical Services. CoreRx supports contract drug development for the following: Solid Oral (tablets, multi-layered tablets, ODT; capsules, multi-particulate drug delivery); API/Drug substance in capsules/bottles; Semi-solids (creams, ointments, lotions, gels); Liquids (oral liquids, injectables, suspensions, ophthalmics)
Key facts about CoreRx
- Founded Year: 2006
- Location: Clearwater (United States)
- Stage: Acquired
- Total Funding till date: $15M
- Employee Count: 419 as on Apr 30, 2026
- Investors: QHP Capital, JVC Investment Partners and 2 Others
- Latest Funding Round: Series A, Mar 21, 2019, $*****
- Highlight: Acquired
5. InformedDNA
Provider of network of genetics experts to help patients and providers. The website provides information about the genetic counseling services provided by InformedDNA to both consumers and medical providers and allows them to book an appointment.
Key facts about InformedDNA
- Founded Year: 2007
- Location: St Petersburg (United States)
- Stage: Series A
- Total Funding till date: $19.2M
- Employee Count: 86 as on Aug 31, 2026
- Investors: Frist Cressey Ventures, QHP Capital and 5 Others
- Latest Funding Round: Series A, Dec 23, 2019, $*****
- Highlight: Editors' Pick
QHP Capital's Year-on-Year Investment Trends
Its most recent first time investment was in CoPilot.QHP Capital's Investments by Stage
QHP Capital has made 1 investment in Seed stage.QHP Capital's Investments by Sector
QHP Capital has a diverse portfolio, with companies operating in the Enterprise Applications and HealthTech. Notably, it has invested in 6 Enterprise (B2B) companies, 3 Tech companies, 2 Software companies and 1 company focusing on Saas.QHP Capital's Investments by Geography
QHP Capital has made most investments in United States (1).QHP Capital's recent investments
QHP Capital has not made any investment in 2026 so far.Here are the most recent investments by QHP Capital:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 10, 2023 | United States | Seed | 6154 | - |
Acquired companies in QHP Capital's Portfolio
3 companies from QHP Capital's portfolio have been acquired. The most recent acquisition was Catalyst Clinical Research in Jan 2026 by Worldwide Clinical Trials for $*****.Here are QHP Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 20, 2026 | - | - | 7639 | |
Jan 19, 2021 | - | - | 9419 | |
Aug 04, 2020 | - | - | 4293 |
Team profile of QHP Capital
QHP Capital has a team of 15 members including 4 Partners and 3 Principals located in United States. QHP Capital's team does not sit on the board of any company as of now.Here is a list of top team members in QHP Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Raleigh | - | ||
Partner | Raleigh | - | ||
Partner | Far Hills | - | ||
Partner | - | - | - | |
Principal | Raleigh | - | - | |
Principal | Raleigh | - | ||
Principal | Raleigh | - | - |
Recent News related to QHP Capital
•
Azurity Pharmaceuticals Secures $1.1 Billion Continuation VehiclePulse 2.0•Mar 19, 2026•Audax Strategic Capital, QHP Capital, Azurity Pharmaceuticals, HarbourVest Partners and 1 other
•
•
Spectra Medical Devices Acquires XL Precision TechnologiesBusiness Wire•Sep 30, 2024•Spectra Medical Devices, XL Precision Technologies, QHP Capital
•
Owen Murray Tapped as CEO of Combined Bend Bioscience, CoreRx and Societal EntitiesContract Pharma•Aug 08, 2024•QHP Capital, Aprecia Pharmaceuticals
•
•
•
QHP Capital-Backed Pro-ficiency Acquired by Simulations PlusBusiness Wire•Jun 12, 2024•QHP Capital, Simulations Plus, ProFiciency
•
Principal IRB Becomes Univo IRB With Support From QHP CapitalBusiness Wire•Feb 20, 2024•Univo IRB, QHP Capital
•
•
Private equity firm QHP Capital building an empire on legacy of Quintiles founder Dennis GillingsWRAL TechWire•Jun 16, 2023•QHP Capital

_1564394168101.png?format=webp&height=120&width=120)